INCR:NASDAQIntercure Ltd. Analysis

InterCure Ltd. (INCR) is trading at $0.93, just below its 20‑day SMA of 0.96 but comfortably above the 50‑day SMA of 0.88, indicating a marginal short‑term pullback within a broader neutral trend. The 14‑day RSI sits at 50, reinforcing the lack of clear momentum. A bearish MACD crossover (line = 0.013, signal = 0.027) and a negative histogram add pressure to the downside. Volume has been increasing, suggesting that the recent price moves are supported by market participation. The Fear & Greed Index reads “Extreme Greed,” implying that speculative appetite may be inflating the stock despite weak fundamentals.
Fundamentally, INCR reports zero revenue, a 23.9% “growth” figure that likely reflects a nascent pipeline, and a loss of $55 M in EBITDA with negative free cash flow of $37 M. The price‑to‑book ratio of 0.12 is dramatically low, hinting at an asset‑light undervaluation relative to its book value of $7.59 per share. However, negative earnings, a –13% profit margin, and a debt‑to‑equity ratio above 46 signal serious cash‑burn concerns. Operating in the medical‑cannabis niche places the company under high regulatory scrutiny, especially given its Israeli base and international ambitions. High 30‑day volatility (≈ 83%) and a beta near 1.0 further amplify the risk profile, while modest market capitalization (~$53 M) and thin average volumes raise liquidity questions. In this context, the stock appears cheap on a balance‑sheet basis but carries significant execution and regulatory risk that must be priced in.